Because abnormal CRT activation is often observed in human hepatocellular carcinoma (HCC), we evaluated whether aplykurodin A was able to downregulate CRT in SNU475 and Hep3B hepatoma cells that displayed elevated CRT because of an inactivation mutation in AXIN1, a critical component of destruction complex [27,28]. This evidence concerns the gene AXIN1 and hepatocellular carcinoma.